Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Influenza vaccine uptake in juvenile idiopathic arthritis during the COVID-19 pandemic : a multi-centre cross-sectional study by PRES vaccination working party
Avtorji:ID Maritsi, Despoina (Avtor)
ID Alpert, Noa (Avtor)
ID Bizjak, Maša (Avtor)
ID Ziv, Amit (Avtor)
ID Balažiová, Barbora (Avtor)
ID Toplak, Nataša (Avtor), et al.
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (956,89 KB)
MD5: 6FB7E1D4D9338CD5671FED8746E5952D
 
URL URL - Izvorni URL, za dostop obiščite https://link.springer.com/article/10.1186/s12969-025-01158-4
 
Jezik:Angleški jezik
Tipologija:1.03 - Drugi znanstveni članki
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Background: Children with rheumatic diseases are at risk for contracting severe influenza and COVID-19 and are thus targeted for these vaccination. Objectives: To assess the influenza (flu) vaccination rate in children with Juvenile Idiopathic Arthritis (JIA), investigate families’ attitudes towards the influenza vaccine, and the effect of the COVID-19 pandemic on flu vaccine uptake. Methods: This multi-centre, cross-sectional study was conducted across 9 countries. JIA caregivers completed an anonymous questionnaire about their children’s influenza vaccination, including the 2019–2020 and 2020–2021 seasons, including knowledge, and perceptions regarding influenza vaccination. Results: Based on responses from 655 JIA caregivers, 152 children (23.2%) received influenza vaccinations in the 2020–2021 season, representing a significant rise from 18.6% in the previous season (p < 0.01). The likelihood of vaccination was higher among employed/self-employed caregivers compared to unemployed (28.2% and 29.9% vs. 13.9%), and those with tertiary education versus elementary (28% vs. 9.7%), both p < 0.01. Concerns of children’s vulnerability to SARS-CoV-2 and severe COVID-19 disease due to JIA were prevalent (51.3% and 85.3% respectively), with 51.3% supporting COVID-19 vaccination. Caregivers who previously vaccinated their children for influenza showed a greater inclination towards SARS-CoV-2 vaccination (73.4% and 79.5%, p < 0.01). Conclusions: Families of children with JIA reported an increasing flu vaccine uptake and a high intention for COVID- 19 vaccine administration. Previous vaccination behavior was shown as a significant predictor of future behaviour. Strengthening health education may address fears and lead to better vaccine coverage against both influenza and SARS-CoV-2 in children with JIA and other inflammatory rheumatic diseases.
Ključne besede:influenza vaccine, juvenile idiopathic arthritis, JIA, COVID-19, vaccination, children
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-7
Številčenje:Vol. 23, [article no.] ǂ103
PID:20.500.12556/DiRROS-24637 Novo okno
UDK:616-002
ISSN pri članku:1546-0096
DOI:10.1186/s12969-025-01158-4 Novo okno
COBISS.SI-ID:253825027 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 20. 10. 2025;
Datum objave v DiRROS:09.12.2025
Število ogledov:83
Število prenosov:69
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Pediatric rheumatology online journal
Skrajšan naslov:Pediatr. rheumatol. online j.
Založnik:University of Chicago, University of Chicago, BioMed Central
ISSN:1546-0096
COBISS.SI-ID:21482457 Novo okno

Gradivo je financirano iz projekta

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Univerzitetni klinični center Ljubljana
Številka projekta:20250018
Naslov:Varnost, imunogenost in učinkovitost cepljenja otrok z imunsko posredovanimi boleznimi, ki prejemajo imunosupresivno terapijo (preverjanje imunogenosti cepiva za tetanus in hepatitis B ter T celični odziv na cepivo za hepatitis B; nadaljevanje- zaključna faza projekta za cepljenje z živimi oslabljenimi cepivi pri otrocih na biološki terapiji)

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Nazaj